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obesity is a pandemic associated with a high incidence of cardiovascular disease; however, the 
mechanisms are not fully elucidated. proteomics may provide a more in-depth understanding of the 
pathophysiological mechanisms and contribute to the identification of potential therapeutic targets. 
thus, our study evaluated myocardial protein expression in healthy and obese rats, employing two 
proteomic approaches. Male Wistar rats were established in two groups (n = 13/group): control diet 
and Western diet fed for 41 weeks. Obesity was determined by the adipose index, and cardiac function 
was evaluated in vivo by echocardiogram and in vitro by isolated papillary muscle analysis. proteomics 
was based on two-dimensional gel electrophoresis (2-DE) along with mass spectrometry identification, 
and shotgun proteomics with label-free quantification. The Western diet was efficient in triggering 
obesity and impaired contractile function in vitro; however, no cardiac dysfunction was observed 
in vivo. the combination of two proteomic approaches was able to increase the cardiac proteomic 
map and to identify 82 differentially expressed proteins involved in different biological processes, 
mainly metabolism. furthermore, the data also indicated a cardiac alteration in fatty acids transport, 
antioxidant defence, cytoskeleton, and proteasome complex, which have not previously been 
associated with obesity. Thus, we define a robust alteration in the myocardial proteome of diet-induced 
obese rats, even before functional impairment could be detected in vivo by echocardiogram.
Obesity is a complex metabolic disease that may lead to severe damage to health, and its prevalence worldwide 
has nearly tripled since 1975, according to the World Health Organization1. In 2016, over 650 million adults were 
obese, and if this current trend continues, it will reach increasingly alarming numbers1,2. Obesity has been con-
sidered a common global pandemic disease, imposing a heavy burden on public health with a profound impact 
on morbidity and mortality, and health care costs3.
Considerable clinical and experimental evidence has associated obesity with an increased risk for the devel-
opment of various comorbidities4. Furthermore, obesity is recognized as an independent and increasingly preva-
lent risk factor for cardiovascular disease (CVD)5. The excess of adipose tissue may promote maladaptation that 
results in alterations in cardiac structure and systolic and, particularly, diastolic function, which subsequently 
may progress to heart failure depending on the severity and duration of obesity6,7. The mechanisms underlying 
functional impairment of the heart in obesity are complex and incompletely elucidated, and disturbances in 
pathways at the cardiomyocyte level, myocardium, and heart chambers may be involved8. Indeed, alterations in 
cardiac energy metabolism of the cardiomyocyte, particularly involving fatty acids, play a significant impact on 
cardiac function and efficiency, contributing to the development of obesity-related cardiomyopathies9.
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The high level of technological advance in equipment and methods of analysis is leading to a more precise 
understanding of the mechanisms responsible for pathophysiological processes. One of the research approaches 
that has been highlighted is proteomics10. In cardiovascular medicine, proteomics aims to evaluate the changes 
in protein expression under disease conditions, to better understand their role in the pathophysiological basis of 
cardiac dysfunction. Such studies may stimulate the discovery of new diagnostic or prognostic biomarkers and 
the development of new therapeutic applications for combating heart disease11.
Many studies have investigated the heart proteome in different experimental and clinical non-obese models 
with atherosclerosis, myocardial ischemia, dilated cardiomyopathy, myocardial infarction, and heart failure12–16. 
However, alterations in the cardiac proteome related to obesity have been little explored. Some investigations 
were found in genetic models of obesity17,18 or dietary models using a high-fat diet19–21; such studies deployed 
different proteomic methods and were not always associated with cardiac dysfunction. Even in the absence 
of cardiac dysfunction in Western diet-induced obese animals, the cardiac proteome was subtly altered when 
assessed by label-free shotgun proteomics22. Other studies have evaluated changes in proteins associated with 
diastolic dysfunction of the heart that exhibit oxidative post-translational modification, via tandem mass-tagging 
approaches23,24.
Here, we aim to evaluate patterns of protein expression in the myocardium of obese rats induced by Western 
diet. For this purpose, we performed two different proteomic approaches: two-dimensional electrophoresis 
(2-DE) with mass spectrometry (MS) based-identification of differentially expressed spots, and shotgun pro-
teomics followed by label-free quantification. The results of this study will aid understanding of the mechanisms 
inherent in cardiac remodelling in obesity.
Materials and Methods
Animal models and experimental protocol. Sixty‐day‐old male Wistar rats were housed in individ-
ual cages in a controlled environment under a 12-h light-dark cycle at a room temperature of 24 °C ± 2 °C and 
humidity of 55 ± 5%, with a free supply of food and water. Rats were randomly assigned to two groups (n = 13 for 
each group): control diet (C: 3.6 kcal/g among which 11% kcal from fat, 67% from carbohydrate, and 22% from 
protein) and Western diet (WD: 4.9 kcal/g among which 50% kcal from fat, 35% from carbohydrate, and 15% 
from protein). Each group was fed the respective diet for 41 weeks. The following ingredients were used in diets: 
corn bran, soybean hulls, soybean bran, dextrin, sucrose, fructose, soybean oil, palm kernel oil, palm oil, lard, 
salt, and vitamin and mineral complex. The control diet was custom-formulated with the same ingredients as the 
WD except for lard, palm oil, sucrose, and fructose, which were added only in the WD, and soybean oil, only in 
the control diet (Supplementary Table S1).
At the end of the experiment, the rats were fasted for 12 h, anesthetized (50 mg/kg ketamine; 10 mg/kg 
xylazine; i.p.), and euthanized by decapitation. Heart tissue was dissected, and then the left ventricle (LV) was 
removed and immediately freeze-clamped at the temperature of liquid nitrogen. Blood samples were collected, 
and the serum was separated by centrifugation at 1620 g for 10 min at 4 °C.
All the experiments were conducted following the Guide for the Care and Use of Laboratory Animals pub-
lished by the National Research Council (2011) and approved by the Ethics Committee on Animal Experiments 
of the Botucatu Medical School, São Paulo State University (1169/2016-CEUA).
Nutritional profile and assessment of the comorbidities associated with the obesity. The nutri-
tional profile was evaluated according to the following parameters: food and caloric intake, feed efficiency, body 
weight, body fat, and adiposity index, as previously described25. Food intake and body weight were measured 
weekly. Caloric consumption was determined by multiplying the energy value of each diet (g × kcal) to the food 
intake. The feed efficiency was calculated, dividing the total body weight gain (g) by total energy intake (kcal) in 
order to analyze the animal’s capacity to convert consumed food energy in body weight. Total body fat was deter-
mined as the sum of epididymal, retroperitoneal, and visceral fat pad weights. The adiposity index was calculated 
as follows: (total body fat/final body weight) × 100.
To assess obesity comorbidities, the following parameters were measured: systolic blood pressure (SBP), oral 
glucose tolerance test (OGTT), homeostatic model assessment of insulin resistance (HOMA-IR) and serum lipid 
profile. All the analyses were evaluated as previously described26.
cardiac morphologic study. Macroscopic cardiac remodelling was determined by the following param-
eters: heart, atria and left and right ventricle weights, as well as their ratio with tibia length. Additionally, frozen 
LV samples were used for histologic analysis as previously described27. Briefly, LV transverse sections were cut at 
5 µm thickness in a cryostat cooled to −20 °C and stained with hematoxylin and eosin to determine transverse 
myocyte diameter, which was measured in at least 50–70 myocytes from each LV as the shortest distance between 
borders drawn across the nucleus. Collagen interstitial fraction was also determined using picrosirius red staining 
of LV sections, and on average, 20 microscopic fields were used to quantify interstitial collagen fractional area. 
Perivascular collagen was excluded from this analysis. All the measurements were performed using a Leica micro-
scope (magnification 40×) attached to a video camera and connected to a computer equipped with image analysis 
software (Image-Pro Plus 3.0, Media Cybernetics, Silver Spring, MD, USA).
echocardiographic study. Echocardiograms were performed before euthanasia using a commercially 
available echocardiography (General Electric Medical Systems, Vivid S6, Tirat Carmel, Israel) equipped with a 
5–11.5 MHz multifrequency transducer as previously described25,27. Briefly, two‐dimensionally guided M-mode 
images were obtained from parasternal short‐axis views of the LV just below the tip of the mitral valve leaflets at 
the level of the papillary muscles, and at the level of the aortic valve and left atrium. The following LV structural 
parameters were evaluated: LV diastolic diameter (LVDD), LV diastolic posterior wall thickness (DPWT), LV 
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relative wall thickness (RWT), and diameters of the left atrium (LA) and aorta (AO). LV function was assessed by 
the following parameters: endocardial fractional shortening (EFS), ejection fraction (EF), posterior wall shorten-
ing velocity (PWSV), Tissue Doppler imaging (TDI) of mitral annulus systolic velocity (S′), early and late diastolic 
mitral inflow velocities (E and A waves), isovolumic relaxation time (IVRT), E wave deceleration time (EDT), 
TDI of early mitral annulus diastolic velocity (E′), and myocardial performance index (Tei index).
Myocardial functional analysis. The intrinsic myocardial contractile performance was evaluated by an 
isolated papillary muscle (IPM) study from LV, as previously described28. The following parameters were meas-
ured from isometric contraction: developed tension (DT; g/mm2), resting tension (RT; g/mm2), peak of positive 
(+dT/dt; g/mm2/sec), and negative (−dT/dt; g/mm2/sec) tension derivative. The mechanical behaviour of IPM 
was evaluated under baseline condition at 2.5 mM Ca2+ and after the inotropic manoeuvres: post-rest contraction 
(PRC) and extracellular Ca2+ concentration increase. All manoeuvre values were expressed as the mean percent 
of baseline data and were calculated as follows: D = (M2-M1)/M1 × 100, where M1 was the value in the baseline 
condition, and M2 was the value after the inotropic manoeuvres. All force data were normalized for muscle 
cross-sectional area (CSA). To avoid the central core hypoxia and impaired functional performance, IMP with 
CSA > 1.5 mm2 were excluded from the analysis.
Proteomic analysis based on 2-DE followed by LC-MS/MS. For full experimental details of this 
analysis, see supplementary materials and methods. Briefly, the 2-DE analysis was performed using a pooled 
homogenized LV sample (11 animals in each group); the pool was analysed as three technical replicates. For the 
first dimension, the isoelectric electrophoresis focusing was performed with Immobiline DryStrip pH gradient 
3–10 (13 cm in length) strips in an Ettan IPGphor 3 Isoelectric Focusing System (GE Healthcare). For the second 
dimension, the electrophoresis was carried out in a SE 600 Ruby electrophoresis systems (Ge Healthcare). Gels 
were scanned using Image Scanner III calibrated densitometer and analysed using Image Master 2D Platinum 
software (version 7.05, GE Healthcare). Protein spots with p-value < 0.05 and at least a 1.2-fold difference in 
abundance were considered as differentially expressed. These protein spots were manually cut from the gels, 
digested in-gel with trypsin (PROMEGA), and further identified by MS.
The MS analyses were performed using a quadrupole model mass spectrometer (MicrQ-TOF III; Bruker 
Daltonics) with an electrospray ionization source and coupled to a liquid chromatography (LC-20AT; Shimadzu). 
The MS data were processed by Bruker Data Analysis software (version 3.3, Bruker Daltonics) and analysed using 
Mascot v.2.1 (www.matrixscience.com) to identify the proteins. The following search settings were used: trypsin 
enzyme, one permitted miscleavage, 0.1 Da peptide tolerance, 0.1 Da fragment ion mass tolerance, methionine 
oxidation as a variable modification, carbamidomethylation of cysteine as a fixed modification, and Rattus nor-
vegicus taxonomy in NCBI database (151,390 sequences; 75,214,998 residues – March 2017).
Shotgun proteomics followed by label-free quantification. For full experimental details of this anal-
ysis, see supplementary materials and methods. Briefly, LV samples from eight individuals in each of the control 
and WD groups (non-pooled samples) were used to perform the analysis. For the in-solution digestion, a fixed 
amount of protein from each sample (100 μg) was initially incubated at 80 °C with RapiGest (0.05% w/v final con-
centration, Waters, Manchester, UK) and then digested using sequencing grade trypsin (Promega). The cleared 
peptide digests were analyzed using a Q-Exactive HF Hybrid quadrupole-Orbitrap mass spectrometer (Thermo 
Fisher Scientific, Hemel Hempstead, UK) coupled to a Dionex Ultimate 3000 RSLC nano-liquid chromatography 
(Thermo Fisher Scientific, Hemel Hempstead, UK). The MS raw data files were loaded into Progenesis QI for 
Proteomics v.4.0 (Nonlinear Dynamics, Waters, Newcastle upon Tyne, UK) to perform the quantitative analysis. 
The peak list was searched against the UniProt database of Rattus norvegicus using Mascot v.2.6 (Matrix Science, 
London, UK) (7,989 sequences; 4,044,314 residues – January 2018). Trypsin was the specified enzyme, and one 
missed cleavage was allowed. Carbamidomethylation of cysteine was set as a fixed modification and oxidation of 
methionine as a variable modification. A precursor mass tolerance of 10 ppm and a fragment ion mass tolerance 
of 0.01 Da were applied. The false discovery rate was set at 1%. The criteria to consider a protein significantly up- 
or down-regulated were: identification and quantification using at least two unique peptides and q-value < 0.05.
Protein expression of all proteomic data was displayed in a volcano plot according to their statistical p-value 
and their relative difference of abundance (i.e., fold change), using an online tool (https://paolo.shinyapps.io/
ShinyVolcanoPlot/). The relative expression levels of the differentially expressed proteins across the experimental 
groups were visualized using heatmap generated with a web tool for visualizing the clustering of multivariate data 
ClustVis29. Unsupervised multivariate principal component analysis (PCA) was also built using ClustVis.
proteomic bioinformatics. All the differentially expressed proteins obtained from 2-DE and shotgun pro-
teomic were subjected to enrichment analysis for the Gene Ontology (GO) terms “molecular function”, “biologi-
cal process” and “cellular component” using Protein ANalysis THrough Evolutionary Relationships (PANTHER, 
v.13.1) bioinformatics tool (http://www.pantherdb.org)30. The protein-protein interaction networks were con-
structed using the online STRING database (https://string-db.org) version 11.0. All STRING network analyses 
were performed with a medium confidence level (0.4).
Western blot analysis. To verify some of the differentially expressed proteins via 2-DE and shotgun pro-
teomics, we conducted Western blot analysis for two proteins involved in lipid metabolism, as platelet glycopro-
tein 4 (Cd36) and fatty acid-binding protein (Fabp3). The following primary antibodies were used: anti-Cardiac 
Fabp (1:1000; ab133585, Abcam, Cambridge, MA, USA), and anti-CD36 (1:1000; ab133625). For full experimen-
tal details of this analysis, see supplementary materials and methods.
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oxidative stress biomarkers analysis. Malondialdehyde (MDA) and protein carbonylation levels were 
measured as oxidative stress biomarkers in cardiac tissue. For full experimental details of this analysis, see sup-
plementary materials and methods.
Statistical analysis. Prior to further statistical analysis, all datasets were tested for normality using the 
Shapiro-Wilk test. Data are expressed as mean ± SD or median (Min-Max) and were subjected to Student’s t‐
test or Mann-Whitney U-test for independent samples. The IPM function after the inotropic intervention was 
evaluated by ANOVA on the model of repeated measures for independent groups and complemented by the 
Bonferroni post hoc test for multiple comparisons. All tests performed were two-sided, and adjustments for mul-
tiple comparisons were applied where indicated. The level of significance considered was 5%. The statistical anal-
yses were performed using SigmaPlot 12.0, and graphics were generated using GraphPad Prism 8.
Results
Effects of WD on nutritional, metabolic, and cardiovascular profiles. Prolonged exposure to WD 
caused increased final body weight, total body fat, and adiposity index, leading to obesity in the animals fed on 
this diet (Table 1). Although the food and caloric intake were lower, the feed efficiency was higher in the WD 
group, which led them to gain more weight than the control group (Table 1). The body weight showed a slight 
increase of 10% in the rats fed WD, while the adiposity index presented a significant rise of 85%. Therefore, the 
continuous feeding of a WD was efficient in promoting obesity in 41 weeks. Long-term WD-induced obesity led 
to significant cardiovascular and metabolic disorders. The SBP, AUC, HOMA-IR, insulin hormone, and serum 
levels of glucose and triacylglycerol were higher in the WD group than the control (Table 1). Thus, WD-fed rats 
recapitulated many features of metabolic syndrome, including glucose intolerance, insulin resistance, dyslipi-
daemia, and arterial hypertension. All these results are consistent with previous investigations31,32 and make the 
WD-fed animals an appropriate model to study obesity-linked complications.
Effects of obesity on cardiac structure and function. The morphological study indicated that obese 
rats did not trigger cardiac hypertrophy and interstitial collagen accumulation since there was no significant 
difference between the groups in parameters as ratios of heart, atria and left and right ventricle weights with the 
tibia length, as well as transverse myocyte diameter and interstitial collagen fraction (Supplementary Table S2).
Regarding the echocardiography (Table 2), the data revealed only a statistically significant reduction in EFS 
and EF in the WD group after 41 weeks. Also, the PWSV showed a trend toward being decreased in the WD 
group (p = 0.089). Despite the significant decrease in EFS and EF, this change varied by 7% and 2%, respec-
tively, indicating a modest alteration in the systolic function that may not reflect pathophysiologic significance. 
Although both systolic and diastolic dysfunctions have been found in obesity, several studies have been contro-
versial in the dysfunction pattern33,34. Some authors also observed only significant decreased EF and/or EFS by 
echocardiography in obese animals32,35, in agreement with our results. It is noteworthy that cardiac performance 
in vivo depends on contractile muscle properties. However, several factors can also change the cardiac function, as 
preload, afterload, and heart rate, which suffer the influence of different stimulus as the hormonal and autonomic 
nervous systems36.
Thus, we also evaluated the myocardial function in vitro by studying IPM at baseline and after inotropic 
manoeuvres (Fig. 1), which detects changes in the contractility of IPM, even with controlled afterload, preload, 
heart rate, energetic substrate and without hormonal and nervous system influence. The CSA of IPM did not 
differ between the groups (control = 1.01 ± 0.21, WD = 1.13 ± 0.22 mm2; p = 0.161). The IPM study, at baseline, 
evidenced diastolic dysfunction due to raised resting tension in the WD group (Fig. 1A), suggesting increased 
Variables Control (n = 13) WD (n = 13) p-value
Initial body weight, g 175 ± 26 177 ± 25 0.819
Final body weight, g 557 ± 50 613 ± 81 0.043
Total body fat, g 32.9 ± 8.4 68.6 ± 27.0 <0.001
Adiposity index, % 5.9 ± 1.2 10.9 ± 2.9 <0.001
Food intake, g 25.9 ± 2.3 16.7 ± 2.0 <0.001
Caloric consumption, kcal 93.4 ± 8.2 81.7 ± 9.6 0.003
Feed efficiency, % 1.43 ± 0.13 1.86 ± 0.14 <0.001
SBP, mmHg 125 ± 4 151 ± 23 0.027
Glucose, mg/dL 97 ± 9 109 ± 13 0.019
AUC, mg.dL−1.min 25,249 ± 2,908 32,140 ± 6,391 0.002
Insulin, ng/mL 0.92 ± 0.51 1.55 ± 0.61 0.011
HOMA-IR 5.7 ± 3.0 10.5 ± 4.3 0.006
Triacylglycerol, mg/dL 82 ± 35 109 ± 30 0.007
Total cholesterol, mg/dL 75 ± 14 71 ± 15 0.474
HDL, mg/dL 23 ± 3 24 ± 4 0.557
Table 1. The nutritional profile and parameters associated with obesity. Values are means ± SD. Student’s t-
test for independent samples. SBP: systolic blood pressure. AUC: area under the curve for glucose. HOMA-IR: 
homeostasis model assessment of insulin resistance. HDL: high-density lipoprotein.
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myocardial stiffness, which may be caused by elevation of collagen and cytosolic Ca2+ concentration, and/or ATP 
deficit37. In the current study, no rise in myocardial collagen was observed in the WD group, implying that the 
increased myocardial stiffness was probably due to impaired Ca2+ and/or ATP signalling. However, it is note-
worthy that although collagen is the predominant component of the cardiac extracellular matrix, there are other 
proteins, e.g., fibronectin, secreted protein acidic and rich in cysteine (SPARC), and collagen cross-linking, which 
have also been associated with myocardial stiffness38–40. Figure 1B indicates that PRC induced a positive inotropic 
response in control and WD groups after cessation of the stimulus. However, this effect was significantly dimin-
ished in the WD group after 30 and 60 secs in the parameters DT, +dT/dt, and −dT/dt, indicating both systolic 
and diastolic dysfunction. As the PCR manoeuvre evaluates the release and recapture of Ca2+ by the sarcoplasmic 
reticulum (SR), this behaviour observed in the WD group can be attributed to impairment in Ca2+ reuptake by 
SR Ca2+-ATPase (ATP2A2), Ca2+ release by ryanodine receptor (RYR2) or affinity of Ca2 binding in troponin C. 
The Ca2+ stimulation manoeuvre showed no difference in the systolic functional parameters between the groups 
(Fig. 1C); this fact suggests that the most probable hypothesis is that the RYR2 function and Ca2+ binding in 
troponin C are not damaged in the WD group. Taken together, the results suggest cardiac dysfunction due to 
possible damage in the proper functioning of ATP2A2.
The divergence of results using different methodologies is probably attributable to the sensitivity and biologi-
cal environment in which the evaluations were performed. Despite the functional changes in the IPM study, they 
were not of sufficient intensity to cause cardiac dysfunction in vivo, as assessed by echocardiography.
Identification of differentially expressed proteins using 2-DE-based proteomics. The analysis 
showed that the triplicate 2D gels of the control and WD groups (Supplementary Fig. S1) were very similar, with 
correlation values greater than 0.90, ensuring reproducibility and quality, and reducing errors due to technical 
variations during electrophoresis (Fig. 2A). Software screening counted mean values of 490 and 503 spots respec-
tively from control and WD 2‐DE gels. Most spots were resolved approximately in the 25–80 kDa molecular mass 
range and by the 5–9 pH area. The analysis revealed 47 significantly altered spots, and of these, we observed 27 
increased, and 20 decreased in the WD group. A representative gel indicating the 47 spots is shown in Fig. 2B. 
Seven proteins, namely ECH1, ACADL, ACOT2, ENO1, ENO3, DLAT, MYH6, were identified in two resolved 
spots, possible protein isoforms or post-translational modifications, thus adjusting the total to 40 unique altered 
proteins. The detailed list of the 40 differently expressed proteins is provided in Supplementary Table S3.
Identification of differentially expressed proteins using shotgun proteomic. The analysis allowed 
the identification and quantification of a total of 1226 proteins in the myocardial tissue extracts. This was reduced 
to 869 proteins by the addition of a further criterion of identification by a minimum of two unique peptides. Of 
these 869 proteins, 47 were significantly different between the groups (q < 0.05), with 23 and 25 proteins showing 
an increase or decrease in abundance, respectively, in the WD group relative to the control group (Supplementary 
Table S4).
All data were visualised by a volcano plot to demonstrate the level of significance and magnitude of changes 
observed in the proteomic data, comparing the WD with the control group (Fig. 3A). The abundance of a small 
Variables Control (n = 11) WD (n = 11) p-value
Heart Rate, bpm 235 ± 23 236 ± 23 0.978
LVDD, mm 7.98 ± 0.49 7.85 ± 0.35 0.507
DPWT, mm 1.38 ± 0.06 1.42 ± 0.05 0.129
RWT 0.35 ± 0.03 0.36 ± 0.02 0.174
LA/AO 1.37 ± 0.10 1.43 ± 0.07 0.102
EFS, % 55.7 ± 3.9 52.1 ± 3.3 0.030
EF 0.91 ± 0.02 0,89 ± 0,02 0.029
PWSV, mm/s 43.9 ± 5.5 40.5 ± 3.1 0.089
S’, cm/s 3.91 ± 0.31 4.08 ± 0.29 0.191
E, cm/s 77.3 ± 6.1 76.5 ± 8.3 0.816
A, cm/s 52.4 ± 7.4 50.7 ± 5.2 0.554
E/A 1,50 ± 0,19 1,52 ± 0,17 0.785
IVRT, ms 27.5 ± 3.3 28.6 ± 2.8 0.413
EDT, ms 58.0 ± 8.4 53.8 ± 3.7 0.158
E’, cm/s 4.51 ± 0.66 4.70 ± 0.38 0.423
E/E’ 17.4 ± 2.9 16.4 ± 2.5 0.379
Tei index 0.44 ± 0.05 0.47 ± 0.03 0.186
Table 2. Echocardiographic structural and functional data. Values are means ± SD. Student’s t-test for 
independent samples. LVDD, left ventricle (LV) diastolic diameter; DPWT, LV diastolic posterior wall 
thickness; RWT, relative wall thickness; LA, left atrial diameter; AO, aortic diameter; EFS, endocardial fractional 
shortening; EF, ejection fraction; PWSV, posterior wall shortening velocity; S’, tissue Doppler Imaging (TDI) 
of systolic velocity of the mitral annulus; E and A, early and late diastolic mitral inflow velocities, respectively; 
IVRT, isovolumic relation time; EDT, E wave deceleration time; E’, TDI of early mitral annulus diastolic velocity; 
Tei index, myocardial performance index.
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subset of proteins was markedly changed between the groups. Unsupervised PCA (Fig. 3B) and hierarchical 
clustering analysis (Fig. 3C) of all differentially expressed proteins show an evident separation between the two 
experimental groups, while there was some variance among the biological replicates.
Biological functions of the differentially expressed proteins. We used two different proteomic 
approaches with distinct strengths and weaknesses to increase the breadth and confidence in the analysis. 
Combined, these analyses revealed 87 differentially expressed proteins in obese rat myocardium, and the list of 
the main proteins with their respective biological functions is summarized in Table 3. The two approaches iden-
tified different proteins, but most of them belong to the same functional category, and detected just five proteins 
in common (ACOT2, ECI2, ECH1, MCCC2, and ENO3) (Table 3). Indeed, our results demonstrated that the two 
methods (one based at the protein level, the other at the peptide level) are complementary, and using them in par-
allel may provide a more detailed understanding of the protein expression and molecular mechanisms of change.
Protein-protein interaction analysis linked most of the altered proteins, showing a relationship between them 
(Fig. 4A). The majority of the proteins with changed abundance in the myocardium of obese rats were related 
to metabolic processes, which are represented by green circles (false discovery rate: 9.71e-32). Moreover, the 
network analysis also highlighted strong bias towards lipid metabolism, being the functional category with the 
highest number of changed proteins.
Figure 1. Left ventricular papillary muscle study. (A) Baseline condition, (B) post‐rest contraction and (C) 
effects of increasing extracellular Ca2+ concentration in isolated papillary muscle from control and Western 
diet (WD) groups (n = 11/group). DT, developed tension (g/mm2); RT, resting tension (g/mm2); +dT/dt, peak 
of positive tension derivatives (g/mm2/sec); −dT/dt, peak of negative tension derivatives (g/mm2/sec). All 
parameters normalized per cross-sectional area. Data are means ± SD. Student’s t-test for independent samples 
in (A) and repeated-measures two-way ANOVA and Bonferroni post hoc test in (B) and (C). *p < 0.05 vs. 
control.
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The fold change of all altered proteins varied up to an approximately 3-fold difference in abundance when 
comparing WD with the control group (Fig. 4C). In respect of cardiac metabolism, obese animals displayed 
protein alterations involved in the oxidation of different energetic substrates used for the production of ATP. The 
increase of proteins implicated in fatty acid oxidation was accompanied by a reduction in the proteins associated 
with oxidation of glucose and amino acids. In addition, the WD group also showed a decrease in most pro-
teins involved in the tricarboxylic acid (TCA) cycle, electron transport chain (ETC), and ATP-synthase complex 
(Fig. 4C).
GO enrichment analysis showed that the altered proteins were focused on distinct molecular functions. The 
activities involved in cellular metabolism, particularly in lipid metabolism, constituted the most prominent cate-
gory in molecular function (Fig. 4B). Most of the enriched pathways for GO Biological Process emphasised lipid 
metabolism, highlighting fatty acid β-oxidation. The majority of proteins included in these biological processes 
displayed higher expression in obese animals. Those proteins that were reduced the most play a role in different 
biological processes, such as glutathione metabolism, ETC, glucose and glutamate metabolism, TCA cycle, cel-
lular carbohydrate metabolism, and leucine catabolism. A similar number of proteins up- and down-expressed 
were involved in ATP synthesis process and antioxidant defences. Furthermore, most proteins in the cardiac con-
traction process were increased (Fig. 4B). Finally, GO Cellular Component analysis suggested that the majority of 
changed proteins are mitochondrial. Altered proteins also highlighted the peroxisome and sarcomere (Fig. 4B).
For better visualization of the key molecular alterations identified by the proteomic study inside the cardiomy-
ocyte, Fig. 5 highlights these proteins according to the magnitude of their change (WD versus Control).
Validation of proteomic data by protein expression profiles. We performed western blot analysis 
to verify some of the differentially expressed proteins found by proteomics. We selected two critical proteins of 
lipid metabolism, such as Cd36 (identified by shotgun) and Fabp3 (identified by 2-DE), which play a role in the 
translocation of fatty acids across the sarcolemma of cardiac myocyte, and in fatty acids intracellular transport, 
respectively. The WD group showed higher protein expression for Cd36 and Fabp3 by Western blot (Fig. 6A,B), 
thus confirming the proteomic data.
oxidative stress biomarkers analysis. Metabolic alterations in obesity lead to increased reactive oxygen 
species (ROS) and oxidative stress. Based on the dysregulation of protein expression involved in antioxidant 
defence (Table 3 and Fig. 4B), which act to combat ROS, in the LV from obese rats, we hypothesized that indica-
tors of oxidative stress such as MDA and protein carbonyl levels must be altered in these animals. The WD group 
presented higher values of MDA and protein carbonyl than the control group (Fig. 6C,D). Cardiac oxidative stress 
is thus evidenced by proteomics and by metabolite analyses.
Figure 2. Proteomics data based on 2-DE of heart tissue from control (C) and Western diet (WD) groups. (A) 
Correlation analysis between 2-DE gels triplicates of control (C) and Western diet (WD) groups performed 
by Image Master 2D Platinum software. (B) Representative 2-DE gel image. The position of molecular weight 
(MW) markers are indicated to the right and the pI (isoelectric point) at the bottom of the gel. The sequence 
of numbers (1–47) refers to identification spots of the significantly up- (red circle) and down-regulated (blue 
circle) proteins in the WD group compared to the C group identified by LC-MS/MS. The detailed list of proteins 
for highlighted spots are shown in Supplementary Table S3.
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Discussion
A global molecular view of mechanisms related to cardiac remodelling due to obesity is not yet possible. 
Proteomics is a powerful technology that will provide new information about such biological mechanisms. Thus, 
we performed two different proteomic approaches to screen for protein expression changes in the left ventricle 
from control and obese rats. Overall, our results revealed a broad landscape of changed myocardial proteins and 
the involvement of several molecular networks in an obesity model, even before functional impairment could be 
detected in vivo. The proteomic analysis identified 87 differentially expressed proteins between the groups. The 
most changed proteins were involved in energy metabolism, oxidative stress, contractile and structural architec-
ture, calcium transient, and proteolytic degradation via the proteasome complex.
proteins involved in energy metabolism. The most evident biological process was related to metabolism 
and, in particular, functions related to lipid metabolism. Despite the complex and multifactorial pathophysiology 
of heart damage related to excess adipose tissue, it has been suggested that modifications in cardiac energy metab-
olism are major contributors to cardiac dysfunction41. Obesity appears as a state of increased uptake and oxidation 
of fatty acids (FA) and reduced glucose utilization, which leads to abnormal use of cardiac energy, disturbance of 
myocardial efficiency, and compromised cardiac function41,42. This condition may occur initially due to high levels 
of circulating triglycerides (TG) and free FA and overexpression of FA transporters into cardiomyocytes. This is 
expected, as our study showed changes in FA uptake and both oxidation of FA and glucose in obese animals.
The capture of FA is highly active due to an increased supply of FA coming from TG in obese rats, which 
was accompanied by elevated protein expression of transporters such as CD36 and FABP3. The FABP4 isoform, 
expressed mainly in adipose tissues, was also elevated in the myocardium of obese rats. Interestingly, studies have 
identified FABP4 as a novel adipokine, and serum concentrations have been directly related to heart failure and 
CVD43,44. It is not clear if cardiomyocytes can internalize this protein and take part in the regulation of cellular 
responses45. However, a recent study demonstrated that FABP4 is expressed in the cardiomyocytes and can promote 
cardiac hypertrophy by activating ERK signal46. Our study shows a possible early expression of this protein even 
in the absence of hypertrophy signs, contributing in some way to the dysregulation of cardiac metabolic disorders.
Figure 3. Label-free proteomics data clustering of heart tissue from control (C) and Western diet (WD) groups. 
(A) Univariate, significance (p-value) vs. fold change analyses highlighting several significant deregulated 
proteins of interest. (B) Unsupervised multivariate principal component analysis (PCA). (C) Hierarchical 
clustering analyses (Heatmap) using unsupervised Euclidean distance of all differentially expressed proteins 
between the groups. The detailed description of protein names is shown in Supplementary Table S4.
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One of the main metabolic fates of excess intracellular FA is mitochondrial oxidation, supported by the 
increased expression of enzymes involved in mitochondrial β-oxidation. FA β-oxidation rates are enhanced in 
hearts from mice subjected to diet-induced obesity47. In addition to elevated mitochondrial β-oxidation, our 
results suggest that this process is also active in peroxisomes, as the ABCD3 and HSD17B4 proteins are increased. 
Peroxisomes have also been proposed to exert a kind of “safeguard” of cellular survival against cell toxicity by an 
excess of cellular lipids, thus preventing an overload of mitochondrial β-oxidation and lipotoxicity48,49. Research 
on cardiac injury has focused almost exclusively on the mitochondria, even though comparable processes, such 
as ROS production and the degradation of lipids, are also carried out by peroxisomes and thus deserve further 
attention50.
Our findings also demonstrated that compartments of the cardiac cell in the WD group appear to be altered 
in an attempt to reduce metabolites originating from excess FA, in order to regulate lipid homeostasis within the 
cardiomyocyte. This response has occurred both within the mitochondria (CRAT, ACOT2, and ACSF2) and in 
the cytoplasm (ACOT7) (Fig. 5).
In addition to changes in FA and glucose metabolism, proteins related to amino acid metabolism were mostly 
decreased in the WD group. Amino acid catabolism plays a major role in the production of TCA cycle inter-
mediates51 and this decrease may suggest compromised TCA cycle activity. A recent study showed decreased 
branched-chain amino acids (BCAA) oxidation in hearts from obese mice; however, the authors state that the 
mechanism for the reduction in oxidation rates is unclear because changes in BCAA oxidation proteins were 
not observed52. Our data presented alterations in four proteins of BCAA degradation, three of which displayed 
lower levels in obese animals, supporting the evidence of reduced BCAA oxidation by a decrease in catabolic 
enzymes. A rise in BCAAs and/or BCAA intermediates can stimulate cardiomyocyte growth (hypertrophy), alter 
autophagy, impair mitochondrial function, and trigger ROS formation, contributing to cardiac dysfunction53. 
Further studies are needed to determine the potential contribution of defective BCAA metabolism in obesity to 
cardiovascular impairment.
We observed a decreased abundance of proteins of the TCA cycle, ETC, and ATP-synthase complex in the 
myocardium of obese rats, consistent with impaired energy production. Despite higher β-oxidation, the low 





Receptor and transport of fatty acids CD36; FABP3; FABP4 —
Mitochondrial β-oxidation DECR1; HADHB; HADHA; ECI1; ECI2* ACADVL; ACADL; ECH1*; ECHS1 —
Peroxisome β-oxidation ABCD3; HSD17B4 —
Lipid Homeostasis CRAT; ACOT2*; ACOT7 ACSF2
Glucose metabolism
Glycolysis ENO1 ENO3*; PGAM2; HK2
Glycogen catabolism — PYGM
Glycogen biosynthesis — GYS1
Conversion of pyruvate to acetyl-CoA PDK4 PDHA1; DLAT
Amino acid metabolism
BCAA oxidation HIBADH BCAT2; MCC2*; IVD
Aspartate biosynthetic process — GOT2
Proline catabolic process to glutamate — ALDH4A1
Malate-aspartate shuttle — SLC25A12
Tricarboxylic acid cycle MDH1 IDH2; ACO2; ALDH5A1
Oxidative phosphorylation
Electron transport chain COX5B; ETFA NDUFS1; NDUFS2; ETFDH
ATP-synthase complex ATP5F1D ATP5F1A
Energy transduction — CKM
Antioxidant defence PRDX3; PRDX5; SOD1; GSTA4 PRDX6; GLO1; GSTM2; GSTO1; GSTZ1
Proteasome complex — PSMB5; PSMA7
Cytoskeleton SPTBN2; JUP; SYNPO; FHL2; MYO1C —
Contraction
Contractile proteins MYL2 MYH6
Regulatory proteins of Ca2+ handling ATP2A2; RYR2 —
Table 3. The biological function of the main up- and down-regulated proteins in the WD group compared to 
their controls identified by proteomics. BCAA: branched-chain amino acids. The detailed description of protein 
names is shown in Supplementary Tables S3 and S4. *Equally detected by proteomic based on 2-DE gel and 
shotgun approach. Proteins typed in bold font were detected by 2-DE gel, and not bold font ones, by shotgun 
approach.
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we also observed increase in some proteins involved in the TCA cycle, ETC, and ATP-synthase complex. This 
imbalance in oxidative phosphorylation systems may perhaps be compromising the production of ATP in obese 
animals. These results are further supported in our study by the decreased level of creatine kinase (CKM), which 
provides ATP in the sarcoplasm.
proteins involved in oxidative stress. The release of ROS exceeding endogenous antioxidant capacity 
can indicate oxidative stress. Metabolic alterations observed in the obese heart, mainly increased FA oxidation, 
mitochondrial dysfunction, and glucose autoxidation raise ROS release; prolonged exposure or inappropriate 
subcellular localization of ROS may have detrimental cardiac effects56. Our proteomic data evidenced several 
changed proteins involved in antioxidant defence mechanisms against oxidative stress.
Two antioxidant enzymes located within the mitochondria (PRDX3 and PRDX5), responsible for ROS detoxi-
fying mainly hydrogen peroxide (H2O2), presented higher levels in obese rats. In addition, we observed increased 
expression of two cytosolic enzymes (SOD1, GSTA4). These findings likely reflect a compensatory response to 
combat ROS elevation. Others have also reported increased antioxidant defences in obese hearts57,58.
Obese animals also showed low levels of enzymes involved in defence mechanisms. We observed reductions 
in the protein expressions of three different types of glutathione S-transferases (GSTM2, GSTO1, GSTZ1), whose 
Figure 4. Biological functions of the differentially expressed proteins in the myocardium of obese 
rats identified by proteomics (A) Protein-protein interaction network. The interaction network analyses were 
built using the STRING online software with a medium confidence level (0.4). The circles represent proteins, 
while the straight lines represent the interactions between different proteins. The line thickness indicates the 
strength of evidence, with thicker connections indicating higher confidence in the protein-protein interaction. 
Green circles represent the proteins involved in metabolic processes; shaded area delimits the proteins involved 
in lipid metabolic processes. (B) Gene ontology (GO) enrichment analysis. The analysis was performed using 
the PANTHER tool (http://www.pantherdb.org), providing the significantly enriched GO terms Molecular 
Function, Biological Process, and Cellular Component. On the left panel, the horizontal axis indicates the 
significance (−log10 p-value) of the functional association, which is dependent on the number of proteins 
in the class. On the right panel, changes are displayed as the number of proteins with increased or decreased 
levels (horizontal axis). (C) Violin plot of the fold changes for up- and down-regulated proteins in the WD 
group compared to their controls. The fold changes of up- and down-regulated proteins were further separated 
into the metabolic processes associated with fatty acid, glucose, amino acid, tricarboxylic acid (TCA) cycle, 
and oxidative phosphorylation (Oxi. Phosp.). The circles inside the plots represent the changed proteins. The 
detailed description of protein names is shown in Supplementary Tables S3 and S4.
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role is to remove the endogenously produced free radicals and eliminate electrophilic xenobiotic compounds 
and products of lipid peroxidation such as 4-hydroxynonenal59. Previous work has shown decreased glutathione 
S-transferase enzyme in hearts from obese mice60. Another protein that presented lower levels was PRDX6, which 
plays an essential role in antioxidant defence and turnover of cellular phospholipids, providing a complete sys-
tem for the repair of peroxidised cell membranes61. Additionally, in the WD group, Glyoxalase 1 (GLO1) was a 
down-regulated protein. This enzyme detoxifies methylglyoxal (MG), a potent precursor of advanced glycation 
end-products (AGEs). MG is mostly produced during glycolysis, however, hyperglycaemia, hypoxia, ischemia, 
inflammation, and oxidative stress, while simultaneously inhibiting the activity of GLO1, leading to intra- and 
extra-cellular accumulation of MG and hence AGEs. In emerging studies, GLO1 has been implicated in diabetic 
cardiomyopathy, coronary artery disease (CAD), and myocardial infarction62–64. A recent study has shown that 
a diet supplemented with bioactive compounds, capable of inducing increased expression of GLO1, produced 
improved metabolic and vascular health in overweight and obese subjects65.
Antioxidant defences act through the synergism between their components, some of them being more acti-
vated and others diminished depending on the location and intensity of the oxidative aggression. Taken together, 
our results showed a disruption in proteins related to antioxidant capacity, suggesting cardiac oxidative damage in 
obese rats. To confirm this hypothesis, we further evaluated oxidative stress biomarkers in LV, which were altered 
in the WD group. Therefore, the dysregulation of the protein expressions involved in antioxidant defence has not 
been sufficient to contain the pro-oxidant state found in obesity.
proteins involved in structural architecture and contractile function. The cardiac cytoskeleton has 
recently emerged as a crucial player for maintenance of myocyte integrity. In addition to providing mechanical 
support, these structures are critical for contractile function, tension sensing, and signal transduction, as well as 
support for networks for transport of molecules and organelles66. Disorders in cytoskeletal components have been 
strongly associated with cardiac pathologies67.
Figure 5. Overview of the obesity effects over cardiomyocyte proteome. The identified proteins are shown 
according to the magnitude of fold-change; red color for proteins up-regulated and blue color for proteins 
down-regulated in the myocardium of Western diet-induced obese rats compared to their controls. ROS, 
reactive oxygen species; AGEs, advanced glycation end products; Val, Ile, and Leu, valine, isoleucine, and 
leucine; BCAA, branched-chain amino acids; P5C, pyrroline-5-carboxylate; OAA, oxaloacetate; α-KG, 
α-ketoglutarate; TCA, tricarboxylic acid cycle; SSA, succinate semialdehyde; I, II, III, IV, and V, complexes of 
mitochondrial oxidative phosphorylation (I-IV: respiratory chain complexes; V: ATP synthase complex); CK, 
creatine kinase; Cr, creatine; PCr, phosphocreatine; SR, sarcoplasmic reticulum. The detailed description of 
protein names is shown in Supplementary Tables S3 and S4.
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Our study revealed a higher protein abundance of the cytoskeleton in obese animals, as SPTBN2, JUP, 
SYNPO, FHL2, and MYO1C. In the heart, the SPTBN2 and JUP have established roles in mechanical function, 
and alterations in these proteins are associated with heart failure and cardiomyopathy68–70. However, the roles 
of SYNPO, FHL2, and MYO1C proteins are less well understood. The SYNPO protein was first discovered as an 
actin-associated protein in kidney podocytes and postsynaptic densities of telencephalic synapses71. Two proteins 
from the synaptopodin family, namely myopodin/synaptopodin 2 and synaptopodin 2-like protein/CHAP, are 
highly expressed in the sarcomere Z-disc of the heart muscle72,73. The SYNPO family remains poorly understood, 
and it was not possible to identify which family belongs to the SYNPO identified in our study. Regarding the 
FHL2, little prior work has evaluated its role in cardiovascular disease; however, evidence indicates that FHL2 
Figure 6. Pathways validation of proteomic data. The protein expression levels of (A) platelet glycoprotein 
4 (CD36) and (B) fatty acid-binding protein (FABP3) were measured by Western blot and normalized to 
beta-actin (internal control) in myocardium from control and Western diet (WD) groups (n = 4–6/group). A 
representative Western blot and quantification of protein levels are shown. Images of blots have been cropped; 
the full-length blots are presented in Supplementary Fig. S2. Cardiac levels of (C) malondialdehyde (MDA) and 
(D) carbonylated protein of control and WD groups (n = 8–13/group). Values are mean ± SD or median (Min-
Max). Student’s t‐test (in A, B, and D) or Mann-Whitney U-test (in C) for independent samples.
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inhibits hypertrophic pathways of rat myocytes74, and it is associated with autophagy in mouse aortic endothelial 
cells75. Finally, the MYO1C, unconventional myosin, is an actin-associated molecular motor protein involved 
in the transport of vesicular cargo, including the trafficking of Glut4 glucose transporter, epithelial Na + chan-
nel, podocyte protein Neph1, and NF-κB essential modulator76–78. Recent studies have shown novel knowledge 
regarding the function of MYO1 in the dynamic regulation of cellular processes in different tissues and cells79,80, 
but its role in cardiac injury remains unknown.
Despite the fact that the changes in cytoskeleton components have already been found in obese hearts, such as 
titin and desmin22,81, interestingly, our data highlighted alterations in several cytoskeletal proteins not previously 
associated with obesity, providing novel and remarkable insights into the functioning of the cytoskeleton in this 
pathological condition.
We also observed altered proteins involved in the contractile function. The MYL2 showed higher expression in 
obese rats, while MYH6 was decreased. Reduced MYH6 and MYL2 have been found in hearts from obese animals 
with functional damage82,83, partially corroborating our data.
proteins involved in myocardial ca2+ handling. A higher abundance of intracellular Ca2+-cycling pro-
teins, the sarcoplasmic reticulum Ca2+-ATPase (ATP2A2) and ryanodine receptor (RYR2), was also observed in 
obese animals. These proteins play an essential role in regulating myocardial contraction/relaxation by regulating 
calcium transient homeostasis. Thus, changes in proteins involved in coordinating Ca2+ movement may contrib-
ute to contractile dysfunction84. The cardiac dysfunction in papillary muscle analysis evidenced possible damage 
to the proper functioning of ATP2A2. We hypothesize that the compromise in ATP production can lead to the 
inadequate functioning of this protein since it is ATP-dependent. Further, oxidative stress due to enhanced ROS 
production could induce oxidative post-translational modifications (PTMs) in ATP2A2, leading to depressed 
activity85. Functional damage in this protein may have triggered high expression as a compensatory mechanism; 
however, this elevation appears to be inadequate to maintain the heart function properly. Impairment in Ca2+ 
reuptake by ATP2A2 can decrease the concentration of this ion in SR and, consequently, the amount available for 
release, via RYR2, during systole37; this may be the possible explanation for the increased protein expression of 
RYR2 in the obese group in order to potentiate the Ca2+ release from RS.
proteins involved in proteasome complex. Our proteomics data showed increased proteasome pro-
teins, as PSMB5 and PSMA7, in obese animals. Proteasomes are responsible for the degradation of intracellu-
lar protein, including unneeded or damaged proteins. The cardiac proteasome contains different proportions of 
subunits, and alterations in their composition affect overall proteasome proteolytic activity leading to the accu-
mulation of damaged or misfolded protein. Such protein accumulation can contribute to pathogenesis in cardi-
omyopathies, as seen in non-obese models86,87. Impaired proteasomal degradation may be a feature of late stages 
of obesity and diabetes since failing hearts from chronically obese humans with type-2 diabetes accumulate of 
non-degraded protein88,89. Interestingly, our findings support this theory and provide new insights regarding the 
changed proteasome complex in obesity.
conclusions
In conclusion, the WD model was effective in promoting obesity and features of metabolic syndrome. Moreover, 
our findings showed that although myocardial functional study in vitro revealed impaired contractile function, 
analysis in vivo did not display cardiac dysfunction in obese rats. The combination of two proteomic approaches 
provided broader results, allowing the identification of an important number of altered myocardial proteins in 
a model of diet-induced obesity. These proteins are involved in critical biological processes, mainly in energy 
metabolism. These data will help develop novel hypotheses, but future studies are needed to elucidate the role of 
these changed proteins in cardiac remodelling in obesity.
note. For all protein symbols obtained from proteomic study and cited throughout the text, please, check 
their descriptions in the Supplementary Tables S3 and S4.
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